US Mein Dawaiyon Ke Import Par Chhedkhani, India Ki Tension Badhi
Aajkal, US government ne ek badi investigation shuru ki hai. Yeh investigation is baat par hai ki dusre deshon se dawaaiyan aur unke ingredients import karne se US ki national security par kya asar padta hai. Isse India ki pharmaceutical companies thodi pareshan hain, kyuki woh US ko har saal kareeb $10 billion ki dawaaiyan export karti hain.
India Se US Ko Dawaiyon Ka Supply Khatre Mein?
US Commerce Department is baat ki jaanch kar raha hai ki foreign pharmaceutical imports par depend rehne se US ke healthcare system ko koi khatra toh nahi hai. India, Ireland, Germany, Switzerland aur kuch European countries ke saath, US ko dawaiyan supply karne wale top 5 countries mein se ek hai. 2015 se 2023 ke beech, India ka US pharmaceutical imports mein hissa 6% se badhkar 11% ho gaya hai. Lekin European suppliers ne apna hissa barkarar rakha hai, jaise Ireland ka ab 28% aur Germany ka 21% hissa hai.
Trump Administration Bhi Thi Chinta Mein
Yeh investigation US Trade Expansion Act ke Section 232 ke under ho rahi hai. Is section se government yeh decide kar sakti hai ki specific imports se national security ko khatra hai ya nahi. Pehle bhi is section ka use steel aur aluminium par tariffs lagane ke liye kiya ja chuka hai. Trump administration ne bhi offshore production par depend rehne ko lekar US pharmaceutical industry ki aalochna ki thi.
Generic Drugs Ka Kya Hoga?
India se US ko export hone wali dawaiyon mein generic drugs ka bada hissa hai. Yeh dawaiyan US healthcare system ke liye important hain aur har saal $400 billion se zyada ki savings karwati hain. China is segment mein abhi chhota player hai, lekin agar koi naye tariffs lagte hain toh supply chains badal sakte hain ya prices badh sakte hain.
Indian Companies Par Kitna Asar?
Indian companies par is investigation ka asar unke US market exposure par depend karega. Gland Pharma Ltd. aur Aurobindo Pharma Ltd. apni revenue ka kareeb 50% US se kamaati hain, jabki Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd. aur Lupin Ltd. ka 38-45% exposure hai. Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd. aur Torrent Pharmaceuticals Ltd. bhi US market mein kaafi active hain.
Aage Kya Hoga?
Abhi yeh dekhna baaki hai ki is investigation ke kya results nikalte hain aur Indian pharmaceutical companies par iska kya asar padta hai. Yeh ek breaking news hai jiske updates hum aapko dete rahenge.
